The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...

These drugs have gained popularity for their ability to reduce body weight by suppressing appetite and slowing digestion.

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Trump administration eyes Medicare and Medicaid coverage for weight loss drugs like Wegovy and Ozempic in a five-year pilot ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock gain as Trump administration to trial Medicare, Medicaid coverage for ...